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Summary
Objectives: Malaria kills approximately 1.5 to 2.7 million people each year. Despite the intro-
duction of artemisinin-based combination therapies (ACTs), the treatment of malaria is hampered
by problems such as inadequate efficacy, recrudescence, early re-infection, low patient com-
pliance, and high cost price of drugs. This study tested the hypothesis that the co-formulated
fixed dose combination (FDC) artesunate/sulfamethoxypyrazine/pyrimethamine (As/SMP) admi-
nistered as a 24-hour therapy with a dose interval of 12 hours is as efficacious and safe as the
administration of the same drug over 3 days given with a dose interval of 24 hours, for the
treatment of uncomplicated Plasmodium falciparum malaria in Ivory Coast.
Method: Two hundred and twenty-one patients presenting with uncomplicated P. falciparum
malaria were randomly assigned to either one of the two dosing schemes. Treatment efficacy was
assessed using the current 28-day World Health Organization protocol, success being determined
by absence of recrudescence and parasitemia on day 28.
Results: Both treatment regimenswerehighly efficacious,witha success rateof100% (111/111) for
the 3-day therapy and 99% (109/110) for the 24-hour therapy. Only one patient in the 24-hour
therapy group showed late treatment failure. No serious adverse events or significant laboratory
abnormalities were seen.
Conclusion: The 24-hour therapy is as well tolerated and efficacious as the same medicament
administered over 3 days. This low cost and simplified three-pill treatment is certain to improve
compliance.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +32 (0)14 61 78 20; fax: +32 (0)14 47 29 90.
E-mail address: fhj@dafra.be (F.H. Jansen).
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Malaria therapy has remained a rather difficult task in view
of themultiplicity of the parasites causing the disease and in
particular the resistance these parasites have built up
against the commonly used therapies.1 Modern therapy
has seen the development of artemisinin derivatives such
as artesunate. Treatment is easy and complete, but the
drug must be administered for 5 to 7 days. Improvement
can be obtained by adding a long-acting antimalarial
drug to the artesunate. Common artemisinin-based combi-
nation therapies (ACTs) last for 3 days, but patients have to
swallow no less than 24 pills; examples include the artesu-
nate/amodiaquine co-blister and Coartem1, which contains
artemether and lumefantrine in a fixed dose combination
(FDC). The latter product has been granted ‘essential drug’
status by the World Health Organization (WHO) and is now
being recommended as ‘the’ drug for Africa in the context of
Roll Back Malaria and its financing by the Global Fund. This
‘essential drug’ is relatively good, but recrudescence is real
and re-infection will occur in a number of patients within 28
days after starting therapy.2,3 Its high cost price of US$2.40
per treatment pack is also a problem.
Alternatives are possible; the combination artesunate/
sulfamethoxypyrazine/pyrimethamine (As/SMP; in differ-
ent pills, packed in a co-blister) has been investigated in
comparative randomized studies against the standard FDC
drug artemether/lumefantrine (A/L).3,4 In the study of
Sagara et al. conducted in Bamako (Mali) and involving
300 patients in each group, As/SMP was found to be super-
ior to A/L and showed no recrudescence and far less re-
infection.3 The study carried out in Abidjan (Ivory Coast)
by Penali et al. found similar results with each treatment
(no re-infection, no recrudescence).4 The new combination
did not show side effects or biochemical abnormalities
and was therefore considered to be a potentially useful
drug, particularly if it could be co-formulated in an FDC
tablet. When this FDC formulation was accomplished suc-
cessfully, a new study was undertaken to determine the
profile of the drug when administered as a single pill per
day over 3 days. In addition, the possibility of reducing the
dose interval between tablets to 12 hours in order to limit
the duration of treatment to one day was explored. A first
study was conducted in eastern Sudan.5 The efficacy of As/
SMP FDC administered at time intervals of 12 hours for a
24-hour therapy was compared to the efficacy of the same
drug given as a blister combination (As/SMP Bl) with a dose
interval of 24 hours for 3 days for the treatment of uncom-
plicated Plasmodium falciparum malaria. Seventy-three
patients completed the 28-day follow-up (39 As/SMP FDC
and 34 As/SMP Bl). Polymerase chain reaction (PCR) geno-
typing-adjusted cure rates on day 28 were 92.3% for As/
SMP FDC and 97.1% for As/SMP Bl ( p > 0.05). No serious
adverse events were noted. Based on this good result
and the simplicity of the 24-hour FDC therapy, it was
decided that a new study should be undertaken — the
current controlled randomized comparative study. If this
new FDC ACT treatment is successful, then malaria treat-
ment could be reduced to the intake of three pills in the
course of one day. Such a treatment would be of great
importance for the mass treatment of the African popula-
tion, since it has been estimated that about 500 millioncases of malaria need to be treated each year. Only simple
treatment schemes with efficacious and inexpensive drugs
that do not cause side effects can guarantee optimal
compliance.
Methods
Study center and patients
This open randomized clinical trial (two arms) was carried out
in the vicinity of Abidjan, the capital of Ivory Coast, in
collaboration with the malaria unit of the Pasteur Institute
from Abidjan. The study was started in April 2005, took 2
months, and was carried out based on WHO guidelines.6 The
protocol was reviewed and accepted by the local ethics
committee.
Subjects selected for this study were of both sexes, aged 6
months or older, and presented with uncomplicated P. falci-
parum malaria. These patients were randomly assigned to
two different treatment regimens with the co-formulated
fixed dose combination (FDC) artesunate/sulfamethoxypyr-
azine/pyrimethamine (As/SMP). In group A, three doses
(tablets) were administered orally as a single dose (tablet)
per day over 3 days. In group B, three doses (tablets) were
given as a single dose (tablet) with a dosing interval of
12 hours over 24 hours.
The following patients were included in the study: males
and females aged 6 months and older, with a weight of 5 kg
or more, who presented at the research center during the
study period with symptoms compatible with malaria.
Patients selected to participate were able to take oral
preparations and had an initial temperature of 37.5 8C or
more or had had a fever during the last 24 hours. All
participants were diagnosed with a P. falciparum mono-
specific malaria infection with a parasite density between
1000 and 200 000 asexual forms per microliter of blood. An
informed consent was obtained from each participant or in
the case where the participant was a minor, from the
parents or tutor.
The following patients were excluded: those with
severe or complicated malaria, a serious concomitant
pathology, or those who needed medical treatment incom-
patible with this study objective. Patients who were known
to be allergic to one of the treatment substances, pregnant
women (determined clinically or detected immunologically
by using a b-human chorionic gonadotropin (HCG) test),
individuals who had received an antimalarial treatment
within the 28 days before the inclusion date, and
persons refusing to sign an informed consent were also
excluded.
Objectives
The primary objective was to compare the efficacy of the
‘three-dose As/SMP FDC over 24 hours’ treatment with the
‘three-dose As/SMP FDC over 3 days’ treatment in uncom-
plicated P. falciparum malaria patients. The secondary
objectives were to assess and compare the following out-
comes in the two treatment arms: parasite clearance, fever
clearance, parasitical re-infection rate, and general assess-
ment of therapeutic tolerance.
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The definition of study endpoints and the interpretation of
the results were based on the criteria recommended by the
WHO for efficacy trials in malaria — clinical response.7
The primary endpoint of this study is the adequate
clinical and parasitological response (ACPR) at day 28,
PCR-corrected, which is defined as the absence of para-
sitemia on day 28, irrespective of axillary temperature,
without previously having met any of the criteria of early
treatment failure (ETF), late clinical failure (LCF), or late
parasitological failure (LPF). The ETF criteria are: (1)
development of danger signs or severe malaria on day 1,
day 2, or day 3 in the presence of parasitemia, (2) para-
sitemia at day 2 higher than day 0 count irrespective of
axillary temperature, (3) parasitemia on day 3 with axillary
temperature 37.5 8C, (4) parasitemia on day 3 25% of
count on day 0. The LCF criteria are: (1) development of
danger signs or severe malaria after day 3 in the presence of
parasitemia without previously having met any of the cri-
teria of ETF, (2) presence of parasitemia and axillary tem-
perature 37.5 8C (or history of fever) on any day from day
4 to day 14/28, without previously having met any of the
criteria of ETF. Finally, the LPF criteria are presence of
parasitemia and axillary temperature 37.5 8C on any day
from day 7 to day 14/28, without previously having met any
of the criteria of ETF or LCF.
Recurrent parasitemia after day 7, as in LCF or LPF, is
caused by recrudescence of the original parasite infection or
by a re-infection with a new parasite. Since re-infection
cannot be considered as a treatment failure, it is important
to differentiate recrudescence from re-infection in order to
evaluate the efficacy of an antimalarial drug. This differen-
tiation is done by PCR genotyping of the P. falciparum
merozoite surface protein 1 (msp1), merozoite surface pro-
tein 2 (msp2), and/or glutamate rich protein (glurp), and
correction of the ACPR rates.
The secondary endpoints are the course of the tempera-
ture and the parasitemia. Mean temperatures, the percen-
tage of patients that cleared fever (temperature below
37.5 8C), and the mean parasitemia for both groups on each
follow-up day were calculated and the results were com-
pared. The time of fever clearance, defined as the interval
from the start of the first antimalarial dose until the first time
the body temperature decreased below and remained below
37.5 8C for at least 48 h, was compared for both groups.
Statistical methods
This study was a pilot study and therefore the conclusions
should be considered as exploratory. A minimum of 100
patients needed to be included in each arm. Taking into
account the possibility of a 10% dropout rate, a total of
220 patients were needed for the study.
The treatment efficacy (clinical and parasitological) and
the proportion of undesirable events were compared
between the two treatment arms using a Fisher’s exact test.
The fever clearance was compared between both arms by
the Wilcoxon test. These statistics were calculated by using
the statistical package SAS version 9.1.3, and the 95% con-
fidence intervals were determined using the package Stat-
Xact 3.0.1.8,9The mean temperatures and mean parasitemia were
compared between the arms by the independent samples
t-test using SPSS statistical software.10
Examinations carried out
Recruitment of the patients was undertaken at the local
health center, based on a standard individual questionnaire.
All cases clinically assumed to be malarial were directed for
further clinical, hematological, and parasitological examina-
tion. If clinical and microscopic test results fulfilled the
criteria, patients were included in the study after obtaining
their informed consent.
Clinical follow-up examinations, including measurement
of body temperature and repeated blood smears, were done
on days 1, 2, 3, 7, 14, 21, and 28. In order to distinguish
between recrudescence and re-infection, blood drops were
taken and PCR blots were analyzed for msp1, msp2, and
glurp.
Drug administration
Tablets with a co-formulated FDC of As/SMP were used for
this study. They are available in three different dosage
strengths, so that for each individual one dose corresponds
with one tablet. This means that for adults >40 kg, a tablet
contains 200 mg artesunate, 500 mg sulfamethoxypyrazine,
and 25 mg pyrimethamine; for children and adolescents 16—
39 kg, a tablet contains 100 mg artesunate, 250 mg sulfa-
methoxypyrazine, and 12.5 mg pyrimethamine; and for
babies and infants 5—15 kg, a tablet contains 50 mg artesu-
nate, 125 mg sulfamethoxypyrazine, and 6.25 mg pyrimetha-
mine.
The scored tablets were packed in blisters suited to
tropical conditions: resistant aluminum foil and PVC/PVDC
60 plastic.
Posology and treatment
The subjects were assigned to one of the two arms of the
study according to a randomization list. A total of 221
patients were included, with 111 persons in group A and
110 in group B. Group A was given an FDC of As/SMP in three
doses (1 tablet per dose) over 3 days whereas group B
received three doses (1 tablet per dose) in 24 hours.
All treatments were given at the health center according
to the weight of the participant and were orally administered
in the presence of nursing personnel. An independent blinded
member of personnel evaluated the therapeutic efficacy and
followed up on the side effects.
Care of the patients
Patients who were not present on the predetermined check-
up days (days 1, 2, 3, 7, 14, 21, and 28) were systematically
searched for by local guides and contacted for follow-up.
Patients lost to follow-up were excluded from the study and
replaced.
In the case of treatment failure, patients were excluded
from follow-up (patient’s participation in the study ended)
and they were treated according to the recommendations of
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Figure 1 Flowchart of the study.the National Malaria Control Program. Patients were classi-
fied as ETF or LTF. Patients who developed a concomitant
illness during the 28 days of follow-up were excluded from
follow-up and classification. Rescue treatment was given
according to the national treatment guidelines.
Results
A total of 398 patients were screened of whom 221 fulfilled
the inclusion criteria. After random allocation, 111 patients
ended up in group A (three doses over 3 days) and 110
patients in group B (three doses in 24 hours) (Figure 1).
The baseline characteristics of both groups were similar
(Table 1). All participating individuals could be followed
up for 28 days. No losses to follow-up were seen, so noTable 1 Patient baseline characteristics
Group A Three dose
Number 111
Male/female 52/59
Mean age (95% CI), years 10.17 (8.06—12.28)
Mean weight (95% CI), kg 28.15 (24.62—31.68
Mean temperature (95% CI), 8C 38.75 (38.58—38.92
Mean parasitemia (95% CI), trophozoites/ml 20 112.25 (14 596.6
CI, confidence interval.
a Independent samples t-test.eligible consented patients were excluded and replaced at
any time point.
On days 1, 2, 3, 7, 14, 21, and 28, temperature and
parasitemia were measured and noted in the personal file.
No serious adverse events or significant laboratory abnormal-
ities occurred. Clinical response was excellent in all patients,
and fever disappeared in themajority of cases within 24 hours
(Figure 2). No statistical difference in mean temperature on
each follow-up day was found between the groups (Table 2).
The percentages of patients that had cleared fever on each
follow-up day are given in Table 3. No differences were found
between the groups. The time of fever clearance was also the
same in both treatment arms (p = 0.39).
No statistical difference in mean parasitemia on each
follow-up day was found between the groups (Table 4). Nos in 3 days Group B Three doses in 24 hours p-Valuea
110 -
62/48 -
8.33 (6.94—9.71) 0.151
) 27.06 (23.75—30.35) 0.655
) 38.95 (38.76—39.13) 0.128
7—25 627.83) 16 764.00 (12 814.38—20 713.62) 0.330
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Figure 2 Overview of average temperature on different days. Fever disappeared in the majority of cases within 24 hours. The timing
at first clearance of fever was not significantly different between the two treatment arms ( p = 0.39).
Table 2 Mean temperatures on each follow-up day
Day Group Mean temperature (8C) SD 95% CI of the mean Independent samples t-test
p-Value 95% CI of the difference
(group A  group B)
0 A 38.75 0.9124 38.58—38.92 0.128 0.4488—0.570
B 38.95 0.9937 38.76—39.13
1 A 37.38 0.4010 37.31—37.46 0.399 0.1571—0.0628
B 37.43 0.4279 37.35—37.51
2 A 37.13 0.2546 37.08—37.18 0.214 0.1228—0.0277
B 37.18 0.3103 37.12—37.24
3 A 37.06 0.2606 37.01—37.12 0.371 0.0353—0.943
B 37.03 0.2269 36.99—37.07
7 A 37.06 0.3219 37.00—37.12 0.982 0.0824—0.0844
B 37.06 0.3067 37.00—37.12
14 A 37.05 0.2683 37.00—37.12 0.417 0.0381—0.0917
B 37.03 0.2186 36.98—37.07
21 A 37.02 0.3136 36.96—37.08 0.876 0.0897—0.0765
B 37.03 0.3132 36.97—37.09
28 A 36.97 0.2160 36.93—37.01 0.294 0.0855—0.0260
B 37.00 0.2041 36.96—37.04
SD, standard deviation; CI, confidence interval.
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Table 3 Percentage of patients that cleared fever over time
Day % of subjects that cleared fever Wilcoxon test
Group A (N = 111) Three
doses in 3 days
Group B (N = 110) Three
doses in 24 hours
p-Value 95% CI of the difference
(group A  group B)
1 56.4 65.8 0.17 23%, 4.3%
2 83.6 87.4 0.45 15%, 7.6%
3 96.4 90.1 0.11 2.1%, 16.5%
7 95.5 91.9 0.41 4%, 14.3%
14 99.1 91.9 0.02 0.1%, 16.6%
28 99.1 99.1 1 6.3%, 6.2%
CI, confidence interval.parasitemia was seen after day 2 (Figure 3), but one
patient in the 24-hour treatment group showed LCF on
day 21 as proven by PCR. The results obtained indicate
that both treatment regimens were highly efficacious, with
a success rate of 100% (111/111) for the 3-day therapy
and 99% (109/110) for the 24-hour therapy (Table 5). The
confidence interval (95% CI) of difference in percentages
of the 3-day versus 24-hour treatment was —4.7% to
7.0%.
In conclusion, that the FDC of As/SMP administered within
24 hours was as efficacious and safe as the same drug admi-
nistered over 3 days.
Discussion
In earlier studies, where comparison was made between the
combination As/SMP and A/L, the former combination wasTable 4 Mean parasitemia on each follow-up day
Day Group Mean parasitemia
(trophozoites/ml blood)
SD
0 A 20 112.25 29 322.458
B 16 764.00 20 900.406
1 A 1.09 11.442
B 0 -
2 A 0 -
B 0
3 A 0 -
B 0
7 A 0 -
B 0
14 A 0 -
B 0 -
21 A 0 -
B 194.18 2036.596
28 A 0 -
B 0 -
SD, standard deviation; CI, confidence interval.found to be safe and efficacious. In one of these studies the
superiority of As/SMP over A/L was obvious for the variables
recrudescence and re-infection.3,4 Since technical pharma-
ceutical development has allowed the manufacture of co-
formulated FDC tablets, the opportunity of treating malaria
patients in three tablets has been studied. Pharmacokinetic
considerations have lead to the evaluation of two dose
intervals: 12 and 24 hours.
The standard therapy with artemether and lumefantrine
(Coartem1), recommended by the WHO and granted the
status of essential drug, consists, of an intake of a total of
24 tablets for adults. A single dose corresponds with
four tablets and these should be given six times (at 0,
8, 24, 36, 48, and 60 hours) over 3 days. Alternative
combinations have been investigated to improve treatment
adherence and to make therapy easier for the patient and
for healthcare staff. Initial data published for the FDC95% CI of the mean Independent samples t-test
p-Value 95% CI of the
difference
(group A  group B)
14 543.56—25 767.08 0.330 3408.063—10 104.567
12 805.67—20 836.92
1.08—3.28 0.320 1.071—3.253
-
- - -
- - -
- - -
- - -
-
- 0.320 579.044—190.680
194.29—589.85
- - -
-
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Figure 3 Overview of average number of parasites on different days. No parasitemia was seen after day 2; only one patient in the 24-
hour group was found positive for parasites on day 21 (21 360 parasites/ml blood).combination of dihydroartemisinin/piperaquine, which is a
2-day four-dose treatment,11 is interesting. However, the
product suffers from dihydroartemisinin stability pro-
blems. The combination artesunate/mefloquine is given
over 2 days.12 It is highly efficacious but side effects to
mefloquine are common and the cost price of mefloquine is
high. Artesunate/amodiaquine treatment suffers from a
large number of tablets (24) and is not liked by patients
because of frequent side effects, leading to problems withTable 5 Treatment response
Treatment
response
Group A (N = 111)
Three doses in 3
days
Group B (N = 110)
Three doses in
24 hours
Effective (n) % Effective (n) %
ACPR 111 100 109 99.1
ETF 0 0 0 0
LCF 0 0 1 0.9
LPF 0 0 0 0
Total 111 100 110 100
ACPR, adequate clinical and parasitological response; ETF, early
treatment failure; LCF, late clinical failure; LPF, late parasitolo-
gical failure.compliance. In addition this combination is not free from
recrudescence and re-infections.13 Other combinations of
artesunate with for example Lapdap (lapudrine/dapsone)
also suffer from side effects.14 The combination of arte-
sunate with pyronaridine entered phase II studies only
recently.15In comparison to the other options, the current
version of As/SMP FDC tablets is most promising since it
allows a reduction in the duration of treatment to a total
of 24 h, as well as the option to follow different dose
regimens, such as a dosage over 3 days or prolonged
treatment when considered necessary. Short duration
and a simple dosage regimen are in general approved by
both patients and clinical staff.At the present time, of all
the combinations with artesunate, the one with sulfa-
methoxypyrazine and pyrimethamine is probably one of
the best, and the drug can be used successfully even in
areas with high sulfonamide resistance.16 Credit should be
given to the pharmacokinetic properties of sulfamethox-
ypyrazine (elimination half life of approximately 65 h and
lower protein binding, 65%). The repeated loading dose of
artesunate is responsible for the drastic destruction of
parasites, whereas the sulfamethoxypyrazine/pyrimetha-
mine combination enables the protraction of the favorable
effect to well over 15 days, by continued inhibition of folic
acid biosynthesis in the parasite. Since SMP hardly con-
tributes to the cost of the final pharmaceutical combina-
tion, the price of this new drug can be kept low.
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This article describes a clinical trial carried out in Abidjan,
Ivory Coast, which studied the efficacy of a fixed dose
pharmaceutical composition containing artesunate, sulfa-
methoxypyrazine, and pyrimethamine, in two different
treatment regimens, either three doses over 3 days or three
doses within 24 hours. Based on this study it can be concluded
that it is possible to cure a malaria attack in 24 hours. This
may have important clinical and economical consequences,
because the patient is cured faster and he/she is ready to
restart his/her work or schooling earlier. In addition the drug
has a low cost price.
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